GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and
IRLAB appoints Kristina Torfgård as new CEO marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
IRLAB Appoints Kristina Torfgård as New CEO pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Alzinova AB (publ) ("Alzinova" or "the Company"), announces today that a second external safety review has been carried out of the Company s.
Gothenburg-based Alzinova AB announced today that a second external safety review had been completed with a positive assessment to continue the phase 1b clinical study with ALZ-101 in patients with early Alzheimer's disease (AD). The study investigates two different dose strengths of ALZ-101 during a treatment period of 20 weeks. In total, 26 study participants based in Finland will receive four doses of either ALZ-101 or a placebo.